Company news

Sarepta Therapeutics, Inc. news in 2019

Sarepta Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.

View company

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 31, 2019

Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001

December 22, 2019

Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing

December 12, 2019

Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53

December 11, 2019

Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies

November 13, 2019

Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments

November 6, 2019

Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference

November 4, 2019

Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019

October 23, 2019

Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

October 3, 2019

Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

September 24, 2019

Decks in 2019